Parvus Therapeutics Appoints Dr. Curtis Ruegg as Chief Executive Officer

Burlingame, CA – (BUSINESS WIRE) – Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, announced today the appointment of Curtis Ruegg, Ph.D., as Chief Executive Officer and a member of the Company’s Board of Directors. Dr. Ruegg brings to Parvus over 25 years of leadership experience in the biopharmaceutical industry. Domann- Life Science Leadership conducted the successful search and recruitment of Dr. Ruegg.